©NIJPP
Publications 2026

OPEN ACCESS
ONLINE ISSN: 2992-5479
PRINT ISSN: 2992-605X

NEWPORT INTERNATIONAL JOURNAL OF PUBLIC HEALTH AND PHARMACY (NIJPP)

Volume 7 Issue 1 Page 30-35, 2026

https://doi.org/10.59298/NIJPP/2026/713035

Nano-Enabled Browning of White Adipose Tissue: A Promising Strategy for Obesity-Linked Type 2 Diabetes

Mugisha Emmanuel K.

Faculty of Science and Technology Kampala International University Uganda

ABSTRACT

Obesity-linked type 2 diabetes (T2D) is a growing global health challenge characterized by insulin resistance, chronic low-grade inflammation, and metabolic dysregulation, largely driven by the expansion and dysfunction of white adipose tissue (WAT). In obesity, WAT undergoes hypertrophy and dysfunction, contributing to impaired insulin signaling, elevated free fatty acids, and systemic inflammation. One promising therapeutic approach to combat these metabolic abnormalities is the browning of white adipocytes, a process wherein white adipose tissue adopts characteristics of brown adipose tissue, including increased mitochondrial content and thermogenic capacity. Browning enhances energy expenditure and improves systemic glucose homeostasis. Nanotechnology, with its capacity for targeted and controlled delivery of bioactive molecules, offers unique opportunities to induce browning of WAT. By utilizing smart nanocarriers capable of delivering thermogenic inducers, anti-inflammatory agents, or gene regulators directly to adipocytes, this approach may provide a new avenue for treating obesity-associated insulin resistance and T2D. This review explores the current state of nanotechnology-driven browning strategies, discusses their mechanisms of action, and considers their potential as a transformative therapeutic modality for obesity-linked T2D.

Keywords: nanomedicine, browning, white adipose tissue, obesity, type 2 diabetes, thermogenesis

INTRODUCTION

1. The Pathophysiology of Obesity and Type 2 Diabetes and the Role of White Adipose Tissue

Obesity is a major contributor to the global epidemic of type 2 diabetes (T2D), as excess fat accumulation, particularly in visceral white adipose tissue (WAT), is closely associated with insulin resistance[1–4]. Under normal conditions, WAT serves as an energy storage depot, expanding in response to caloric excess and releasing fatty acids during periods of fasting. However, in obesity, WAT undergoes pathological changes, including adipocyte hypertrophy, reduced insulin sensitivity, and an increase in inflammatory cytokine secretion, all of which promote insulin resistance[5–8]. Large hypertrophic adipocytes, especially in visceral fat depots, are poorly vascularized and more prone to hypoxia, resulting in cell death and the recruitment of macrophages that exacerbate local inflammation.

This inflammatory milieu further impairs insulin signaling, contributing to systemic insulin resistance and the development of metabolic diseases like T2D[9]. In addition, as WAT becomes dysfunctional, it begins to release an excess of free fatty acids (FFAs) into the bloodstream[10–13]. These FFAs are taken up by various tissues, including the liver and skeletal muscle, where they accumulate as toxic intermediates (e.g., diacylglycerols and ceramides), exacerbating insulin resistance and promoting gluconeogenesis. Insulin resistance in these peripheral tissues, combined with impaired β-cell function in the pancreas, ultimately leads to elevated blood glucose levels characteristic of T2D[14–16].

Recent therapeutic efforts have focused on addressing the root causes of insulin resistance, with particular attention on targeting WAT dysfunction. One promising strategy is to induce browning of WAT, which refers to the process by which white adipocytes acquire features of brown adipocytes[17]. Unlike white adipocytes, brown adipocytes are specialized for thermogenesis, containing abundant mitochondria and uncoupling protein 1 (UCP1), which dissipate energy as heat. By promoting the browning of WAT, it is possible to enhance energy expenditure, reduce fat accumulation, and improve systemic insulin sensitivity[17].

Nanotechnology holds immense potential in this area by providing targeted delivery of browning inducers or regulators to adipocytes, bypassing systemic effects and improving therapeutic efficacy[5, 18–22]. Through

OPEN ACCESS
ONLINE ISSN: 2992-5479
PRINT ISSN: 2992-605X

smart nanocarriers capable of releasing their contents in response to environmental cues (e.g., pH, temperature, or reactive oxygen species), this approach can focus on WAT in a controlled manner, minimizing side effects and enhancing treatment precision.

2. The Mechanisms of Adipose Tissue Browning and its Potential in Treating Obesity and Type 2 Diabetes

Adipose tissue browning refers to the process in which white adipocytes acquire features of brown adipocytes, most notably the expression of uncoupling protein 1 (UCP1), a key protein responsible for the thermogenic function of brown adipose tissue[17, 23, 24]. UCP1 uncouples oxidative phosphorylation in mitochondria, diverting the energy from ATP production to heat generation, thereby increasing energy expenditure. Additionally, brown adipocytes are enriched in mitochondria and have an extensive capillary network to support their high metabolic demands[25, 26].

The process of browning is typically regulated by several transcription factors and signaling pathways. Key regulators include PR domain-containing 16 (PRDM16), peroxisome proliferator-activated receptor gamma (PPARγ), and nuclear factor kappa B (NF-κB), which modulate adipocyte differentiation and thermogenic gene expression[27, 28]. Under normal conditions, WAT contains primarily white adipocytes that store energy in the form of triglycerides. However, when exposed to certain stimuli such as cold exposure, β-adrenergic activation, or specific pharmacological agents white adipocytes can undergo transdifferentiation into brown-like adipocytes[28, 29]. This process is known as beiging or browning and is characterized by increased mitochondrial content, elevated UCP1 expression, and enhanced thermogenic capacity[30].

Browning has garnered significant attention as a potential therapeutic strategy for obesity and T2D because it offers a means to increase energy expenditure and promote fat loss without the need for caloric restriction or extreme physical activity. Moreover, browning can have systemic effects on insulin sensitivity[31, 32]. By reducing the size of adipocytes and improving their metabolic activity, browning can ameliorate insulin resistance, particularly in the liver, muscle, and adipose tissue itself. Furthermore, browning may reduce the secretion of pro-inflammatory cytokines by adipocytes, addressing the chronic inflammation that contributes to insulin resistance.

Nanotechnology presents a promising approach to inducing browning in WAT. By using nanoparticles or nanocarriers that can specifically target WAT, researchers can deliver thermogenic agents, such as β3-adrenergic agonists, irisin, fibroblast growth factor 21 (FGF21), or small molecules that activate brown fat-specific transcription factors like PRDM16[18, 20, 33]. Additionally, nanocarriers can deliver gene-regulating agents (e.g., siRNA or CRISPR-based systems) that upregulate key thermogenic genes, such as UCP1, in white adipocytes[34–37]. This targeted delivery not only maximizes the effect on WAT but also minimizes the risk of side effects that could arise from systemic exposure to these potent agents.

3. Nanocarriers for Targeted Delivery of Browning Inducers

Nanocarriers have the unique ability to enhance the delivery of bioactive molecules to specific tissues, overcoming many of the limitations of traditional drug delivery systems. The application of nanotechnology to the browning of WAT is particularly promising because it allows for the targeted release of thermogenic agents directly within adipose depots, maximizing efficacy while minimizing off-target effects[36, 38].

Polymeric nanoparticles, liposomes, and solid lipid nanoparticles (SLNs) are among the most commonly studied nanocarrier systems for browning applications. These carriers are typically composed of biocompatible and biodegradable materials that can encapsulate a wide range of active compounds, including small molecules, peptides, and nucleic acids. One of the key advantages of these nanocarriers is their ability to prolong the release of the active agent, providing a sustained therapeutic effect over time[39–41].

For example, β3-adrenergic agonists, such as clenbuterol or mirabegron, are potent inducers of browning that work by activating β3-adrenergic receptors on adipocytes, promoting lipolysis and mitochondrial biogenesis[42]. However, these compounds often exhibit poor bioavailability and can cause systemic side effects when administered orally. By encapsulating these agents in lipid-based or polymeric nanocarriers, their bioavailability can be significantly improved, and their release can be controlled to ensure sustained activation of browning pathways specifically in adipose tissue[42].

Similarly, FGF21, a hormone that has been shown to induce browning and enhance insulin sensitivity, is another candidate for nanocarrier-based delivery. FGF21 promotes mitochondrial biogenesis and UCP1 expression in adipocytes, and its systemic administration can improve glucose homeostasis. However, FGF21 has a short half-life and is prone to degradation. Encapsulation in nanoparticles can protect FGF21 from enzymatic degradation and enhance its stability and bioavailability, allowing for more effective treatment of obesity and T2D[43].

Another promising approach involves gene delivery via nanocarriers to directly modulate thermogenic gene expression in white adipocytes. By using nanoparticle systems to deliver plasmids or small interfering RNAs (siRNAs) targeting negative regulators of thermogenesis, such as PPARγ or PRDM16, it is possible to upregulate thermogenic gene expression and drive browning of WAT. This approach could provide long-lasting effects by inducing permanent changes in the gene expression profile of adipocytes, thus promoting sustained thermogenesis and improved metabolic function[43].

OPEN ACCESS
ONLINE ISSN: 2992-5479
PRINT ISSN: 2992-605X

4. Mechanisms of Action: Stimuli-Responsive Nanocarriers and Controlled Release

One of the key challenges in nanomedicine is ensuring that the therapeutic agent is released at the appropriate time and location within the body. Smart nanocarriers offer an elegant solution to this problem by incorporating stimuli-responsive components that release their cargo in response to specific environmental cues, such as pH, temperature, or the presence of certain enzymes or reactive oxygen species (ROS)[44–46].

In the case of browning WAT, stimuli-responsive nanocarriers can be engineered to release their thermogenic agents or gene-regulating molecules only within adipose tissue, where they are most needed. For example, pH-sensitive nanoparticles can be designed to release their cargo in the acidic environment of inflamed adipose tissue, ensuring that the active agents are delivered precisely where they can have the greatest impact[47]. Similarly, ROS-sensitive nanoparticles can be used to target adipose tissue in obese individuals, where increased oxidative stress is common. By exploiting the unique microenvironment of inflamed WAT, these carriers can enhance the specificity and effectiveness of the therapeutic agent.

In addition to pH and ROS sensitivity, temperature-responsive nanocarriers are being explored for their ability to release their contents in response to local temperature changes[48]. As adipose tissue undergoes browning, there is often an increase in local temperature due to enhanced mitochondrial activity and thermogenesis[48]. Nanocarriers that release their cargo in response to this temperature change could provide a self-regulating system that adapts to the physiological state of the tissue, providing sustained therapeutic effects without the need for external interventions.

5. Translational Challenges and Future Directions

Despite the promising potential of nanotechnology for browning WAT and treating obesity-linked T2D, several challenges remain in translating these strategies from preclinical studies to clinical applications[49]. One of the major obstacles is the safety and biocompatibility of nanocarriers. Long-term studies are needed to assess the potential toxicity of nanoparticles, especially with repeated administration. Nanocarriers must be designed to degrade into non-toxic metabolites after completing their therapeutic task to avoid accumulation in vital organs such as the liver, spleen, or kidneys[49].

Another challenge lies in scalability and the manufacturing of nanocarriers. While laboratory-scale production of nanoparticles is well-established, scaling up to commercial production levels while maintaining consistency and quality can be difficult. Regulatory approval for nanomedicines is also more complex than for traditional drugs, requiring extensive characterization and validation of each batch to ensure safety and efficacy[50].

Finally, patient stratification will be crucial in the success of nano-enabled browning therapies. Obesity and T2D are highly heterogeneous conditions, and not all individuals may respond equally to browning interventions. Personalized approaches that take into account genetic, metabolic, and environmental factors will be key to optimizing the effectiveness of these therapies.

CONCLUSION

Nano-enabled browning of white adipose tissue presents a novel and promising therapeutic strategy for treating obesity-linked type 2 diabetes. By leveraging the unique properties of nanocarriers, it is possible to deliver thermogenic agents, gene regulators, and anti-inflammatory molecules directly to adipose tissue, promoting the browning of white adipocytes, enhancing energy expenditure, and improving glucose homeostasis. While there are still challenges to overcome in terms of safety, scalability, and patient-specific responses, the potential for nanotechnology to transform the treatment of obesity and T2D is immense. As research progresses, smart nanocarriers could offer a powerful tool for achieving sustainable metabolic improvements and combating the global diabetes epidemic.

REFERENCES

1. Aamodt, K.I., Powers, A.C.: The pathophysiology, presentation and classification of Type 1 diabetes. Diabetes Obes. Metab. 27, 15–27 (2025). https://doi.org/10.1111/dom.16628
2. Abdallah, H., Klink, W.H., Derienne, J., Voican, C., Perlemuter, G., Courie, R., Dagher, I., Tranchart, H.: Interest in Treatment with GLP-1 Receptor Agonists for the Management of Insufficient Weight Loss or Weight Regain After Bariatric Surgery. Obes. Surg. 35, 4286 (2025). https://doi.org/10.1007/s11695-025-08210-y
3. Ahechu, P., Zozaya, G., Martí, P., Hernández-Lizoáin, J.L., Baixauli, J., Unamuno, X., Frühbeck, G., Catalán, V.: NLRP3 Inflammasome: A Possible Link Between Obesity-Associated Low-Grade Chronic Inflammation and Colorectal Cancer Development. Front. Immunol. 9, (2018). https://doi.org/10.3389/fimmu.2018.02918
4. Allocca, S., Monda, A., Messina, A., Casillo, M., Sapuppo, W., Monda, V., Polito, R., Di Maio, G., Monda, M., La Marra, M.: Endocrine and Metabolic Mechanisms Linking Obesity to Type 2 Diabetes: Implications for Targeted Therapy. Healthcare. 13, 1437 (2025). https://doi.org/10.3390/healthcare13121437
5. Alum, E.U.: Circadian nutrition and obesity: timing as a nutritional strategy. J. Health Popul. Nutr. 44, 367 (2025). https://doi.org/10.1186/s41043-025-01102-y

OPEN ACCESS
ONLINE ISSN: 2992-5479
PRINT ISSN: 2992-605X

6. Omang, W.A., Wokoma, M.A., Oplekwu, R.I., Atangwho, I.J., Egbung, G.E.: Combined Hyaluronic Acid Nanobioconjugates Impair CD44-Signaling for Effective Treatment Against Obesity: A Review of Comparison with Other Actors. Int. J. Nanomedicine. 20, 10101–10126 (2025). https://doi.org/10.2147/IJN.S529250
7. Baek, K.-R., Singh, S., Hwang, H.-S., Seo, S.-O.: Using Gut Microbiota Modulation as a Precision Strategy Against Obesity. Int. J. Mol. Sci. 26, 6282 (2025). https://doi.org/10.3390/ijms26136282
8. Bakshi, V., Fathima, B.: Solid Lipid Nanoparticles in Metabolic Disorders: A Novel Strategy for Targeted Delivery in Diabetes and Obesity. J. Bio-X Res. 8, 0066 (2025). https://doi.org/10.34133/jbioxresearch.0066
9. Alum, E.U.: Optimizing patient education for sustainable self-management in type 2 diabetes. Discov. Public Health. 22, 44 (2025). https://doi.org/10.1186/s12982-025-00445-5
10. Uti, D.E., Atangwho, I.J., Omang, W.A., Alum, E.U., Obeten, U.N., Udeozor, P.A., Agada, S.A., Bawa, I., Ogbu, C.O.: Cytokines as key players in obesity low grade inflammation and related complications. Obes. Med. 54, 100585 (2025). https://doi.org/10.1016/j.obmed.2025.100585
11. Acevedo-Román, A., Pagán-Zayas, N., Velázquez-Rivera, L.I., Torres-Ventura, A.C., Godoy-Vitorino, F.: Insights into Gut Dysbiosis: Inflammatory Diseases, Obesity, and Restoration Approaches. Int. J. Mol. Sci. 25, 9715 (2024). https://doi.org/10.3390/ijms25179715
12. Almeida, A.F., Miranda, M.S., Reis, R.L., Gomes, M.E., Rodrigues, M.T.: Using Hybrid Nanoplatforms to Combine Traditional Anti-Inflammatory Drug Delivery with RNA-Based Therapeutics for Macrophage Reprograming. Int. J. Mol. Sci. 25, 10693 (2024). https://doi.org/10.3390/ijms251910693
13. Andersen, P.A.K., Petrenko, V., Rose, P.H., Koomen, M., Fischer, N., Ghiasi, S.M., Dahlby, T., Dibner, C., Mandrup-Poulsen, T.: Proinflammatory Cytokines Perturb Mouse and Human Pancreatic Islet Circadian Rhythmicity and Induce Uncoordinated β-Cell Clock Gene Expression via Nitric Oxide, Lysine Deacetylases, and Immunoproteasomal Activity. Int. J. Mol. Sci. 22, 83 (2021). https://doi.org/10.3390/ijms22010083
14. Armandi, A., Rosso, C., Caviglia, G.P., Bugianesi, E.: Insulin Resistance across the Spectrum of Nonalcoholic Fatty Liver Disease. Metabolites. 11, 155 (2021). https://doi.org/10.3390/metabo11030155
15. Li, M., Chi, X., Wang, Y., Setrerrahmane, S., Xie, W., Xu, H.: Trends in insulin resistance: insights into mechanisms and therapeutic strategy. Signal Transduct. Target. Ther. 7, 216 (2022). https://doi.org/10.1038/s41392-022-01073-0
16. Obasi, D.C., Abba, J.N., Aniokete, U.C., Okoroh, P.N., Akwari, A.Ak.: Evolving Paradigms in Nutrition Therapy for Diabetes: From Carbohydrate Counting to Precision Diets. Obes. Med. 100622 (2025). https://doi.org/10.1016/j.obmed.2025.100622
17. Magro, B.S., Dias, D.P.M.: Brown and beige adipose tissue: New therapeutic targets for metabolic disorders. Health Sci. Rev. 10, 100148 (2024). https://doi.org/10.1016/j.hsr.2024.100148
18. Anjum, S., Ishaque, S., Fatima, H., Farooq, W., Hano, C., Abbasi, B.H., Anjum, I.: Emerging Applications of Nanotechnology in Healthcare Systems: Grand Challenges and Perspectives. Pharmaceuticals. 14, 707 (2021). https://doi.org/10.3390/ph14080707
19. Awlqadr, F.H., Majeed, K.R., Altemimi, A.B., Hassan, A.M., Qadir, S.A., Saeed, M.N., Faraj, A.M., Salih, T.H., Abd Al-Manhel, A.J., Najm, M.A.A., Tsakali, E., Van Impe, J.F.M., Abd El-Maksoud, A.A., Abedelmaksoud, T.G.: Nanotechnology-based herbal medicine: Preparation, synthesis, and applications in food and medicine. J. Agric. Food Res. 19, 101661 (2025). https://doi.org/10.1016/j.jafr.2025.101661
20. Bhange, M., Telange, D.: Convergence of nanotechnology and artificial intelligence in the fight against liver cancer: a comprehensive review. Discov. Oncol. 16, 77 (2025). https://doi.org/10.1007/s12672-025-01821-y
21. Uti, D.E., Alum, E.U., Atangwho, I.J., Ugwu, O.P.-C., Egbung, G.E., Aja, P.M.: Lipid-based nano-carriers for the delivery of anti-obesity natural compounds: advances in targeted delivery and precision therapeutics. J. Nanobiotechnology. 23, 336 (2025). https://doi.org/10.1186/s12951-025-03412-z
22. Ntaobeten, E., Obeten, U.N., Bawa, I., Agada, S.A., Ukam, C.I.-O., Egbung, G.E.: Antioxidants in cancer therapy mitigating lipid peroxidation without compromising treatment through nanotechnology. Discov. Nano. 20, 70 (2025). https://doi.org/10.1186/s11671-025-04248-0
23. Aouadi, M., Vangala, P., Yawe, J.C., Tencerova, M., Nicoloro, S.M., Cohen, J.L., Shen, Y., Czech, M.P.: Lipid storage by adipose tissue macrophages regulates systemic glucose tolerance. Am. J. Physiol. - Endocrinol. Metab. 307, E374–E383 (2014). https://doi.org/10.1152/ajpendo.00187.2014
24. Auger, C., Kajimura, S.: Adipose Tissue Remodeling in Pathophysiology. Annu. Rev. Pathol. Mech. Dis. 18, 71–93 (2023). https://doi.org/10.1146/annurev-pathol-042220-023633
25. Carpentier, A.C.: Tracers and Imaging of Fatty Acid and Energy Metabolism of Human Adipose Tissues. Physiology. 39, 61–72 (2024). https://doi.org/10.1152/physiol.00012.2023

OPEN ACCESS
ONLINE ISSN: 2992-5479
PRINT ISSN: 2992-605X

26. Chait, A., den Hartigh, L.J.: Adipose Tissue Distribution, Inflammation and Its Metabolic Consequences, Including Diabetes and Cardiovascular Disease. Front. Cardiovasc. Med. 7, 22 (2020). https://doi.org/10.3389/fcvm.2020.00022
27. Machado, S.A., Pasquarelli-do-Nascimento, G., da Silva, D.S., Farias, G.R., de Oliveira Santos, I., Baptista, L.B., Magalhães, K.G.: Browning of the white adipose tissue regulation: new insights into nutritional and metabolic relevance in health and diseases. Nutr. Metab. 19, 61 (2022). https://doi.org/10.1186/s12986-022-00694-0
28. Checa-Ros, A., D'Marco, L.: Molecular mechanisms linking adipose tissue browning to reduced cardiovascular risk. Atherosclerosis. 411, 120564 (2025). https://doi.org/10.1016/j.atherosclerosis.2025.120564
29. Wang, L., Shan, T.: Factors inducing transdifferentiation of myoblasts into adipocytes. J. Cell. Physiol. 236, 2276–2289 (2021). https://doi.org/10.1002/jcp.30074
30. Alum, E.U., Izah, S.C., Betiang, P.A., Paul-Chima Ugwu, O., Ainebyoona, C., Uti, D.E., Echegu, D.A., Alum, B.N.: The Ketogenic Diet in Obesity Management: Friend or Foe? Cell Biochem. Biophys. (2025). https://doi.org/10.1007/s12013-025-01878-0
31. Machado, S.A., Pasquarelli-do-Nascimento, G., da Silva, D.S., Farias, G.R., de Oliveira Santos, I., Baptista, L.B., Magalhães, K.G.: Browning of the white adipose tissue regulation: new insights into nutritional and metabolic relevance in health and diseases. Nutr. Metab. 19, 61 (2022). https://doi.org/10.1186/s12986-022-00694-0
32. McNeill, B.T., Suchacki, K.J., Stimson, R.H.: MECHANISMS IN ENDOCRINOLOGY: Human brown adipose tissue as a therapeutic target: warming up or cooling down? Eur. J. Endocrinol. 184, R243–R259 (2021). https://doi.org/10.1530/EJE-20-1439
33. Azmi, N.A.N., Elgharbawy, A.A.M.: Advances in Medical Applications: The Quest of Green Nanomaterials. In: Shanker, U., Hussain, C.M., and Rani, M. (eds.) Handbook of Green and Sustainable Nanotechnology: Fundamentals, Developments and Applications. pp. 1889–1909. Springer International Publishing, Cham (2023)
34. Anwar, D.M., Hedeya, H.Y., Ghozlan, S.H., Ewas, B.M., Khattab, S.N.: Surface-modified lipid-based nanocarriers as a pivotal delivery approach for cancer therapy: application and recent advances in targeted cancer treatment. Beni-Suef Univ. J. Basic Appl. Sci. 13, 106 (2024). https://doi.org/10.1186/s43088-024-00566-x
35. Cheng, H., Liao, J., Ma, Y., Sarwar, M.T., Yang, H.: Advances in targeted therapy for tumor with nanocarriers: A review. Mater. Today Bio. 31, 101583 (2025). https://doi.org/10.1016/j.mtbio.2025.101583
36. Datta, D., Priyanka Bandi, S., Colaco, V., Dhas, N., Siva Reddy, D., Vora, L.K.: Fostering the unleashing potential of nanocarriers-mediated delivery of ocular therapeutics. Int. J. Pharm. 658, 124192 (2024). https://doi.org/10.1016/j.ijpharm.2024.124192
37. George Joy, J., Sharma, G., Kim, J.-C.: Tailoring polymeric nanocarriers for hypoxia-specific drug release: Insights into design and applications in clinics. Chem. Eng. J. 496, 153978 (2024). https://doi.org/10.1016/j.cej.2024.153978
38. Parvin, N., Aslam, M., Joo, S.W., Mandal, T.K.: Nano-Phytomedicine: Harnessing Plant-Derived Phytochemicals in Nanocarriers for Targeted Human Health Applications. Molecules. 30, 3177 (2025). https://doi.org/10.3390/molecules30153177
39. Begines, B., Ortiz, T., Pérez-Aranda, M., Martínez, G., Merinero, M., Argüelles-Arias, F., Alcudia, A.: Polymeric Nanoparticles for Drug Delivery: Recent Developments and Future Prospects. Nanomaterials. 10, 1403 (2020). https://doi.org/10.3390/nano10071403
40. kapoor, D. u, Garg, R., Gaur, M., Prajapati, B.G., Agrawal, G., Bhattacharya, S., Elossaily, G.M.: Polymeric nanoparticles approach and identification and characterization of novel biomarkers for colon cancer. Results Chem. 6, 101167 (2023). https://doi.org/10.1016/j.rechem.2023.101167
41. Wang, X.-Q., Zhang, Q.: pH-sensitive polymeric nanoparticles to improve oral bioavailability of peptide/protein drugs and poorly water-soluble drugs. Eur. J. Pharm. Biopharm. 82, 219–229 (2012). https://doi.org/10.1016/j.ejpb.2012.07.014
42. Cypess, A.M., Weiner, L.S., Roberts-Toler, C., Elía, E.F., Kessler, S.H., Kahn, P.A., English, J., Chatman, K., Trauger, S.A., Doria, A., Kolodny, G.M.: Activation of Human Brown Adipose Tissue by a β3-Adrenergic Receptor Agonist. Cell Metab. 21, 33–38 (2015). https://doi.org/10.1016/j.cmet.2014.12.009
43. Danielak, A., Magierowski, M.: Obesity and mitochondrial uncoupling – an opportunity for the carbon monoxide-based pharmacology of metabolic diseases. Pharmacol. Res. 215, 107741 (2025). https://doi.org/10.1016/j.phrs.2025.107741
44. Du, J., Lane, L.A., Nie, S.: Stimuli-Responsive Nanoparticles for Targeting the Tumor Microenvironment. J. Control. Release Off. J. Control. Release Soc. 219, 205–214 (2015). https://doi.org/10.1016/j.jconrel.2015.08.050

OPEN ACCESS
ONLINE ISSN: 2992-5479
PRINT ISSN: 2992-605X

45. Lee, H., Rho, W.-Y., Kim, Y.-H., Chang, H., Jun, B.-H.: CRISPR-Cas9 Gene Therapy: Non-Viral Delivery and Stimuli-Responsive Nanoformulations. Molecules. 30, 542 (2025). https://doi.org/10.3390/molecules30030542
46. Salehi, S., Naghib, S.M., Garshasbi, H.R., Ghorbanzadeh, S., Zhang, W.: Smart stimuli-responsive injectable gels and hydrogels for drug delivery and tissue engineering applications: A review. Front. Bioeng. Biotechnol. 11, 1104126 (2023). https://doi.org/10.3389/fbioe.2023.1104126
47. Hou, J., Xue, Z., Chen, Y., Li, J., Yue, X., Zhang, Y., Gao, J., Hao, Y., Shen, J.: Development of Stimuli-Responsive Polymeric Nanomedicines in Hypoxic Tumors and Their Therapeutic Promise in Oral Cancer. Polymers. 17, 1010 (2025). https://doi.org/10.3390/polym17081010
48. Karimi, M., Sahandi Zangabad, P., Ghasemi, A., Amiri, M., Bahrami, M., Malekzad, H., Ghahramanzadeh Asl, H., Mahdieh, Z., Bozorgomid, M., Ghasemi, A., Rahmani Taji Boyuk, M.R., Hamblin, M.R.: Temperature-Responsive Smart Nanocarriers for Delivery Of Therapeutic Agents: Applications and Recent Advances. ACS Appl. Mater. Interfaces. 8, 21107–21133 (2016). https://doi.org/10.1021/acsami.6b00371
49. Alanazi, A., Craven, A., Spirou, S.V., Santos-Martinez, M.J., Medina, C., Gobbo, O.L.: Nanomedicine as a Promising Treatment Approach for Obesity. J. Nanotheranostics. 6, 21 (2025). https://doi.org/10.3390/jnt6030021
50. Bi, Y., Xie, S., Li, Z., Dong, S., Teng, L.: Precise nanoscale fabrication technologies, the "last mile" of medicinal development. Acta Pharm. Sin. B. 15, 2372–2401 (2025). https://doi.org/10.1016/j.apsb.2025.03.040

CITE AS: Mugisha Emmanuel K. (2026). Nano-Enabled Browning of White Adipose Tissue: A Promising Strategy for Obesity-Linked Type 2 Diabetes. NEWPORT INTERNATIONAL JOURNAL OF PUBLIC HEALTH AND PHARMACY,7(1):30-35.
https://doi.org/10.59298/NIJPP/2026/713035